Treatment
SHR-A2102 ; Adebrelimab clinical trials
We’re tracking 11 recruiting studies that include SHR-A2102 ; Adebrelimab, each written for real people, not researchers, below.
Recruiting studies
- NCT06417554RecruitingPhase 1/Phase 2
Study of SHR-A2102 for advanced solid tumors
This trial is testing a new drug, SHR-A2102, either alone or with other treatments, for people with advanced solid tumors that have stopped responding to standard therapy. The goal is to see if it can shrink tumors or slow the cancer's growth.
Beijing, Beijing MunicipalityAges 18–80 - NCT07393542RecruitingPhase 3
Combination treatment for advanced bladder cancer
This trial tests a new combination of two medications, SHR-A2102 and adebrelimab, for people with advanced bladder cancer that has not been treated before. The goal is to see if this combination can shrink tumors and help patients live longer.
Beijing, Beijing MunicipalityAges 18–80 - NCT06879145RecruitingPhase 2/Phase 3
Study of SHR-A2102 and Adebrelimab for muscle-invasive bladder cancer
This trial tests a combination of two drugs, SHR-A2102 and Adebrelimab, for people with muscle-invasive bladder cancer that hasn't spread. The goal is to see if this treatment can help control the cancer.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT06639347RecruitingPhase 1/Phase 2
Testing SHR-A2102 for advanced bladder cancer
This trial tests a new drug called SHR-A2102, which is a type of targeted therapy (an antibody-drug conjugate) for advanced urothelial carcinoma (bladder cancer). It may help if your cancer has not responded to standard treatments or if you are starting treatment for advanced disease.
Guangzhou, GuangdongAges 18 years+ - NCT06433609RecruitingPhase 2
ADC plus immunotherapy for advanced HER2-negative breast cancer
This trial tests a combination of an antibody-drug conjugate (ADC) and an immunotherapy drug (adebrelimab) for people with advanced HER2-negative breast cancer that has stopped responding to prior treatments. The goal is to see if this combination can help shrink or slow the cancer.
Beijing, Beijing MunicipalityAges 18–75 - NCT06474468RecruitingPhase 1/Phase 2
Study of a new drug combo for advanced esophageal cancer
This trial tests a combination of two investigational drugs for people with advanced or metastatic esophageal squamous cell carcinoma. The goal is to see if the combination can shrink tumors or slow cancer growth.
Jinan, ShandongAges 18–70 - NCT06512051RecruitingPhase 1/Phase 2
Study of SHR-A2102 and Adebrelimab for advanced lung cancer
This trial tests a combination of two drugs, SHR-A2102 and Adebrelimab, with or without other treatments, for people with advanced or metastatic non-small cell lung cancer that cannot be removed by surgery or cured with radiation. It aims to see if this approach can shrink tumors or slow the cancer's growth.
Beijing, Beijing MunicipalityAges 18–70 - NCT06547736RecruitingPhase 2
Precision treatment for advanced pancreatic cancer
This trial tests personalized therapies for people with advanced pancreatic cancer that has spread or cannot be removed. It aims to find the best treatment based on your tumor's unique features.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06589778RecruitingPhase 1/Phase 2
Study of three drugs for advanced lung cancer
This trial tests a combination of three drugs (SHR-A2102, Adebrelimab, and SHR-8068) for people with advanced non-small cell lung cancer that cannot be removed by surgery. It aims to see if this combination can shrink or slow the growth of the cancer.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT07229729RecruitingPhase 2
Combination therapy for resectable lung cancer
This trial tests a new drug, SHR-A2102, combined with other treatments for people with non-small cell lung cancer that can be removed with surgery. It aims to improve outcomes by using multiple therapies together.
Guangzhou, GuangdongAges 18–70 - NCT07059221RecruitingPhase 1/Phase 2
New drug combo for advanced head and neck cancer
This trial tests a new combination of drugs (SHR-A2102 and Adebrelimab) with or without other anti-cancer therapies for head and neck cancer that has come back or spread. It aims to see if these treatments can shrink tumors or slow the disease.
Chongqing, Chongqing MunicipalityAges 18–75
What SHR-A2102 ; Adebrelimab is being studied for
Conditions with recruiting SHR-A2102 ; Adebrelimab studies.
Common questions
- Are there clinical trials studying SHR-A2102 ; Adebrelimab?
- Yes. Clin2 currently lists 11 recruiting studies that include SHR-A2102 ; Adebrelimab, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a SHR-A2102 ; Adebrelimab trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is SHR-A2102 ; Adebrelimab an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether SHR-A2102 ; Adebrelimab or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.